摘要
芍药苷是芍药科植物中主要且具有代表性的活性成分,在心血管疾病的防治中展现出广泛的药理作用,包括抗动脉粥样硬化、抗心肌梗死、抗血栓及改善心肌缺血再灌注等。然而,其临床应用受到稳定性差、溶解度低、代谢快和口服吸收效率低等因素限制。针对这一难题,近年来多种新型递药系统相继开发,包括微乳、脂质体、磷脂复合物、纳米粒和凝胶剂等,部分制剂在动物实验中显示出良好的组织靶向性和治疗效果。本文总结芍药苷对心血管疾病的保护作用,梳理其剂型优化的最新进展,旨在为其后续药物开发与临床转化提供参考依据。
As a major and representative bioactive compound derived from plants of the Ranunculaceae family,Paeoniflorin has demonstrated a wide range of pharmacological effects in the prevention and treatment of cardiovascular diseases(CVDs),including anti-atherosclerotic,anti-myocardial infarction,anti-thrombotic activities,as well as the amelioration of myocardial ischemia-reperfusion injury.However,its clinical application is hindered by poor stability,low solubility,rapid metabolism,and limited oral bioavailability.To address these challenges,a variety of novel drug delivery systems have been developed in recent years,such as microemulsions,liposomes,phospholipid complexes,nanoparticles,and hydrogels.Some of these formulations have shown promising tissue-targeting properties and therapeutic efficacy in animal studies.This paper summarizes the cardioprotective effects of Paeoniflorin on CVDs and outlines recent advances in formulation optimization,aiming to provide a reference for its further pharmaceutical development and clinical translation.
作者
陈园
杜利新
李涛
王文宇
邹龙
CHEN Yuan;DU Lixin;LI Tao;WANG Wenyu;ZOU Long(School of Pharmacy,Hunan University of Chinese Medicine,Changsha,Hunan 410208,China)
出处
《湖南中医药大学学报》
2025年第7期1394-1400,共7页
Journal of Hunan University of Chinese Medicine
基金
湖南省研究生科研创新课题项目(CX20230830)。
关键词
芍药苷
心血管疾病
新剂型
生物利用度
制剂研究
新型递药系统
Paeoniflorin
cardiovascular disease
novel formulation
bioavailability
formulation research
new drug delivery system
